ZEB2 and breast carcinoma: Kaplan–Meier survival analysis showed that breast cancer patients with low ratio of NMI/ZEB2 (NMI/ZEB2 Lo) had significantly worse (p = 0.02) relapse-free survival compared to patients with a higher ratio (Fig. 6A).